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2007 and 2013. Patients with incomplete data and without 
follow up before treatment, were excluded. All patients 
received the same RT scheme: 33 daily fractions of 1.64 Gy 
to intermediate-risk volume and 2.12 Gy to high-risk volume 
with SIB, reaching 54.12 Gy and 69.96 Gy respectively.  
Descriptive statistics (frequencies and percentages) were 
used to report the characteristics of patients, their clinical 
status, the treatment performed and toxicities reported. The 
oncologic outcomes were overall survival (OS), loco-regional 
relapse-free survival (LRRFS), metastases-free survival (MFS) 
and progression free survival (PFS). These variables were 
estimated using the Kaplan-Meier method (95% CI level). 
Results: The median follow-up was 28.1 months. Median age 
was 49 years (range, 15 - 78). There was a predominance of 
men (67.3%), white race (80.8%). The tumors were 
undifferentiated (WHO III) in 40 patients (76.9%), and EBV 
positive in 33 (63.5%). There was a majority of locally 
advanced disease, with 48 patients (92.3%) stage III-IV. Only 5 
patients (9.6%) were treated exclusively with RT, while the 
rest received chemotherapy (CT), mainly concurrent (84.6%). 
Neoadjuvant CT was delivered to 22 (42.3%) patients, 
adjuvant CT to 4 (7.7%) patients and 15 (28.8%) patients 
received neoadjuvant and adjuvant CT. The 1- and 3-year 
estimation of OS was 98.0% and 85.5%, respectively, while 1 
and 3-year LRRFS were 100% and 95.8%, respectively. 
Conclusions: The treatment of NPC (predominantly locally 
advanced) using IMRT-SIB in our institution, offers a rational 
and feasible alternative of treatment, comparable to results 
described so far in endemic population.  
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Purpose/Objective: To analyse the outcome of all the 
patients treated in our Institute for Nasopharyngeal 
Carcinoma without distant metastasis at diagnosis in a period 
of 14 years. 
Materials and Methods: From January 2000 to December 
2013 187 consecutive patients received radiotherapy +/- 
chemotherapy (neoadjuvant and/or concomitant). 
Results: According to TNM classification, UICC 2009, 31% of 
patients were in stage I-II, 69% in stage III-Iva-b. The 
predominant histologic pattern was WHO type 3 in 70.6% of 
patients. At 10 years Overall Survival (OS) has been 65+/-6%, 
Disease Specific Survival (DSS) 82+/-3%, Loco Regional Control 
(LRC) 73+/-5%, Distant Metastasis Free Survival (DMFS) 63+/-
5%. Many clinical variables (gender, histology, age, T and N 
classification, Stage, Karnofski index) and others related to 
treatment (chemotherapy, waiting time from histological 
diagnosis to first treatment, prolongation of overall radiation 
treatment time, technique of treatment - 3DCRT vs IMRT-, 
fractionation), have been analyzed.At univariate analysis OS 
was statistically related to T and N class, clinical stage, 
Karnofski index, concomitant chemotherapy, respect of 
overall treatment time, modality of irradiation. LRC was 
related to T class, clinical stage, chemotherapy, use of IMRT 
and fractionation (2.3 Gy/fr vs 2 Gy/fr). The DMFS resulted 
related to T class, clinical stage, chemotherapy and time 
between the start of neoadjuvant chemotherapy and 
radiotherapy. At multivariate analysis, the statistically 
significant factors at univariate analysis were considered. For 
OS the final model maintained T class, stage, age, and 
chemotherapy. LRC was related with stage, chemotherapy 
and the use of IMRT. DMFS resulted related to the time 
between start of neoadjuvant chemotherapy and the start of 
radiotherapy (worse results for length of time superior to 30 
days). 
Conclusions: In our single experience the introduction of 
IMRT, frequently associated with IGRT, has been associated 
with a sharp improvement of LRC at 5 yrs (88+/-4% with IMRT 
vs 64+/-7% with 3DCRT, p 0.010), even if we consider the 
association with chemotherapy in various modality 
(neoadjuvant chemo followed by RTT alone or RTT/chemo, 
exclusive radio-chemotherapy or radiotherapy alone). Other 
variables could be involved in this improvement, such as a 
better local definition with MR co-registration during 
planning in the last years, or a better staging with the 
frequent use of CT-PET which can identify cases with distant 
metastasis at first diagnosis. 
The gain obtained with IMRT was also evident in an 
improvement in OS (82+/-5% vs 70+/-5% at 5 yrs, p 0.038) 
while no differences were found in DMFS. The analysis is still 
in progress. 
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Purpose/Objective: To investigate the correlation between 
location of loco-regional failures and previous intensity-
modulated radiation therapy (IMRT) target volumes in 
patients with head and neck (H&N) cancer. 
Materials and Methods: 65 consecutive patients (44 men; 
mean age 59.8 years) presenting with biopsy proven failure 
between May 2011 and April 2014 were retrospectively 
reviewed. Primary tumour location was nasopharynx (n = 4), 
oropharynx (n = 23), oral cavity (n = 11), hypopharynx (n = 4), 
larynx (n = 15), salivary gland (n = 1), primary unknown (n= 
1), and sinus (n = 6). Forty-eight patients had primary and 17 
post-operative (chemo)IMRT. Primary radical doses of 65-
70Gy and 54-56 Gy (30-35 fractions) were delivered to high 
dose (PTV1) and prophylactic (PTV2) target volumes, 
respectively, using a SIB-IMRT technique. In the post-
operative setting the dose to PTV1 was 60-66 Gy (30-33 
fractions). The sites of loco-regional failure (persistent or 
recurrent disease) were delineated on the diagnostic FDG-
PET-CT or CT scans which were co-registered with RT 
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planning scans to transfer relapse volume contours. Failures 
were classified as in-field (>95%), marginal (≥ 20% ≤ 95%) or 
out-field (< 20%) based on the percentage volume that 
received 95% of prescribed dose on visual assessment. 
Results: Overall, there were a total of 74 recurrences in 65 
patients. Nine of these 65 patients had both primary and 
nodal failure, 30 primary failure only, and 26 nodal failure 
only. A total of 39 failures were located within the primary 
tumour area and 35 failures in the neck nodes. The majority 
of loco-regional failures occurred in-field: 85% within PTV1 
and 8% within PTV2. Three failures (4%) were classified as 
marginal and only two (3%) arose out-field. After primary 
(chemo)IMRT, 43 failures occurred in the PTV1 and 5 were 
outside the PTV1 but inside PTV2. No out-field failures were 
observed. In the adjuvant setting, 5 patients had loco-
regional failures outside the PTV1. Dose–volume histogram 
analysis showed that all in-field failures received adequate 
dose coverage relative to the PTV. 
Conclusions: This data analysis suggests that most failures 
occur within the irradiated volume. Considering that 
incidence of geographical misses was low, future studies 
should be directed towards dose escalation in high-risk 
volumes. 
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Purpose/Objective: De-ESCALaTE-HPV is a prospective 
randomised phase III UK radiotherapy trial for low-risk Human 
Papilloma Virus positive oropharyngeal squamous cell 
carcinoma. In December 2013, the trial protocol changed to 
include both anatomical and volumetric outlining to reflect 
UK clinical practice. Centres were required to choose a 
method to delineate targets. The aim of this planning study 
was to quantify the dosimetric impact of these two outlining 
methods on normal tissues, particularly swallowing 
structures.  
Materials and Methods: Ten non-lateralised patients 
recruited to the trial were selected. Gross tumour volumes 
outlined by the recruiting investigators were used. For each 
patient, the high dose clinical target volume (CTV1) using 
anatomic and volumetric methods (Fig. 1), swallowing 
structures (Table 1) and organs at risk (OAR) for the trial 
were delineated by a single clinician. All structures were 
independently verified and modified as required for protocol 
compliance by a second clinician. A standardised class 
solution developed for delivering Volumetric Modulated Arc 
Therapy on CMS Monaco Treatment Planning System was used 
to plan all patients by a single planner. Swallowing structures 
were not used during optimisation. A treatment plan for each 
outlining method was generated for each patient. The 
volume of CTV1, mean dose and partial volume doses (V50, 
V60 and V70) to swallowing structures for each outlining 
method were recorded. Wilcoxon signed-rank test was used 
to compare the difference in doses. 
 
 
Figure 1 showing (a) Volumetric outlining (royal blue) which 
includes the primary Gross Tumour Volume (GTV – red) with a 
1-1.5cm geometric expansion in all directions in high dose 
CTV (CTV1-70Gy 35=); (b) Anatomical outlining (yellow) 
which includes the GTV, a 1-1.5cm margin and the whole 
oropharynx in CTV1; (c) Elective dose CTV (CTV2 – purple; 
56Gy 35=) is similar for both outlining protocols. 
 
Results: The target coverage and OAR doses were 
comparable for each patient between the two outlining 
methods. CTV1 volume was significantly larger using the 
anatomical method. The mean dose was significantly higher 
for all 3 pharyngeal constrictor muscles, supraglottic larynx 
and oral cavity with anatomical outlining. In addition, partial 
volume doses at all measured levels for superior and middle 
pharyngeal constrictor muscles were significantly larger for 
anatomical compared to volumetric method (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
